TECH

Bio-Techne's stock price has been impacted by several events in the past six months. In early May 2026, shares declined over 16% after Q3 fiscal 2026 results missed revenue and EPS expectations. Organic revenue was down 2% year-over-year due to softer Protein Sciences demand and softness in emerging biotech spending. Management guided for flat organic growth in Q4 fiscal 2026, citing cell therapy headwinds. CFRA downgraded the stock to Sell, and Wells Fargo maintained its Overweight rating but cut its price target. Prior to the earnings report, the stock had surged with above-average volume. The stock's 52-week range has been between $45.12 and $72.16.